News from us and our partners

Tags

Topics

0 results

News
17 October, 2024
Noema Pharma Announces NOE-105 (gemlapodect) Phase 2a Study in Tourette Syndrome met Primary and all Key Secondary Endpoints
News
17 October, 2024
Biotalys appoints Kamal El Mernissi as Chief Business Development Officer
News
16 October, 2024
Biotalys announces closing of private placement
News
15 October, 2024
Sofinnova welcomes Agnès Pauquet as Head of Human Resources
News
15 October, 2024
Bio-engineering scale-up Qorium showcases cultivated leather breakthrough, signaling a key step towards commercialisation
News
14 October, 2024
Inventiva announces financing of up to €348 million to advance the NATiV3 Phase 3 MASH study
News
9 October, 2024
Purespring Therapeutics raises £80/$105 million in a Series B financing to transform the treatment of kidney diseases
News
30 September, 2024
Pi-Cardia receives FDA market clearance for ShortCut™
News
25 September, 2024
Genespire raises €46.6 million (~$52 million) in a Series B round to advance its first pediatric in-vivo gene therapy into the clinic
News
23 September, 2024
Sensorion reports new positive clinical results presented at the World Congress of Audiology
News
17 September, 2024
Arzeda secures $38M in oversubscribed funding round to advance protein design commercialization efforts
News
16 September, 2024
AAVantgarde announces first patient dosed with AAVB-081 in FIH Phase 1/2 LUCE-1 study for retinitis pigmentosa related to USH1B
News
12 September, 2024
F2G announces $100 million financing to advance late-stage development and commercialization of novel antifungal drug candidate Olorofim in the US
News
12 September, 2024
Novameat raises €17.4M oversubscribed Series A round led by Sofinnova Partners and Forbion
News
12 September, 2024
Genespire appoints Karen Aiach-Pignet as Chief Executive Officer
News
10 September, 2024
Sofinnova Partners appoints Karl Naegler as Partner

Noema Pharma Announces NOE-105 (gemlapodect) Phase 2a Study in Tourette Syndrome met Primary and all Key Secondary Endpoints

Biotalys appoints Kamal El Mernissi as Chief Business Development Officer

Biotalys announces closing of private placement

Sofinnova welcomes Agnès Pauquet as Head of Human Resources

Bio-engineering scale-up Qorium showcases cultivated leather breakthrough, signaling a key step towards commercialisation

Inventiva announces financing of up to €348 million to advance the NATiV3 Phase 3 MASH study

Purespring Therapeutics raises £80/$105 million in a Series B financing to transform the treatment of kidney diseases

Pi-Cardia receives FDA market clearance for ShortCut™

Genespire raises €46.6 million (~$52 million) in a Series B round to advance its first pediatric in-vivo gene therapy into the clinic

Sensorion reports new positive clinical results presented at the World Congress of Audiology

Arzeda secures $38M in oversubscribed funding round to advance protein design commercialization efforts

AAVantgarde announces first patient dosed with AAVB-081 in FIH Phase 1/2 LUCE-1 study for retinitis pigmentosa related to USH1B

F2G announces $100 million financing to advance late-stage development and commercialization of novel antifungal drug candidate Olorofim in the US

Novameat raises €17.4M oversubscribed Series A round led by Sofinnova Partners and Forbion

Genespire appoints Karen Aiach-Pignet as Chief Executive Officer

Sofinnova Partners appoints Karl Naegler as Partner